Antibody-directed, effector cell-mediated tumor destruction.
about
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyImmunotherapy for pediatric cancer.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Anti-GD2 Strategy in the Treatment of NeuroblastomaAddition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patientsAntibody-based immunotherapy in high-risk neuroblastoma.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Targeted immunotherapy of cancer: development of antibody-induced cellular immunity.Natural killer cells: role in local tumor growth and metastasisIntratumoral immunocytokine treatment results in enhanced antitumor effects.Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.Observation of calcium microdomains at the uropod of living morphologically polarized human neutrophils using flash lamp-based fluorescence microscopyEpigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.Age-related alteration of expression and function of TLRs and NK activity in oral candidiasis.
P2860
Q33785744-2CF6F64A-1F22-4B94-92DC-8768AEDF8D31Q33924586-8CD30A11-2DD8-4B47-80DA-20131A659B03Q34186886-9B3F5864-16F1-4853-B025-DC2C668C8693Q34243887-2CB8EE13-2550-4CC7-A9F8-78332EFC63C7Q34344146-F5CDEB1F-DDC5-48B1-B3FD-39BCAF57014FQ34725758-95D174A9-4289-4AD2-A180-146D830D39B4Q35031732-D1E28313-2B69-4A58-8D55-BC6519C9FE63Q35084986-A05CE459-96F7-49A2-B00E-D67E745F9E53Q35905953-C58E8BD5-FB21-4BE5-A884-663BE93E8272Q36953492-57C4DB97-5B8B-48E0-84EA-82697DF389B8Q37328301-109C0EDB-64E5-402E-9FBC-06DCAA953225Q38570065-C0F6D229-2B94-47A2-8163-F6E261DF61B2Q47305235-DDC69525-AB41-431B-A676-777B27BCEB62Q50583957-6C84E3F7-21E9-4B95-8362-FE2EA0BFBA4F
P2860
Antibody-directed, effector cell-mediated tumor destruction.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antibody-directed, effector cell-mediated tumor destruction.
@ast
Antibody-directed, effector cell-mediated tumor destruction.
@en
Antibody-directed, effector cell-mediated tumor destruction.
@nl
type
label
Antibody-directed, effector cell-mediated tumor destruction.
@ast
Antibody-directed, effector cell-mediated tumor destruction.
@en
Antibody-directed, effector cell-mediated tumor destruction.
@nl
prefLabel
Antibody-directed, effector cell-mediated tumor destruction.
@ast
Antibody-directed, effector cell-mediated tumor destruction.
@en
Antibody-directed, effector cell-mediated tumor destruction.
@nl
P1476
Antibody-directed, effector cell-mediated tumor destruction.
@en
P2093
P304
P356
10.1016/S0889-8588(05)70243-4
P577
2001-08-01T00:00:00Z